Acrivon CHKs itself
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
Zentalis doubles down on Wee1
But the new focus on a predictive biomarker could cut the market in half.
Regeneron keeps up its co-stimulatory crusade
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
